Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey

[...]question remains of whether the adoption of these still largely unapproved regimens for locoregional melanoma metastases into routine clinical practice is justified. [...]melanoma experts nominated by the Melanoma World Society (MWS) and the European Association of Dermato-Oncology (EADO) were surveyed about their opinions and experiences regarding the use of these new therapies for melanoma with locoregional metastasis. [...]the question of which schedule should be introduced first into practice was also answered in favour of the SWOG S1801 schedule (56 [54%] of 104 respondents vs 11 [10%] of 104 respondents for the NADINA or OpACINneo schedule). [...]regarding the approval of neoadjuvant therapies in their countries, 86 (83%) of 104 experts expected the SWOG 1801 regimen to be approved and reimbursed in the next 3 years, while only 52 (50%) of 104 experts foresaw the same for the NADINA or OpACINneo regimen. [...]all experts consider both therapies to be safe enough for patients with resectable locoregional disease (AJCC stage III disease).